Table of Contents

July 15, 2022; Volume 19,Issue 7

C

  1. Chang, Yu

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  2. Chen, Jinghong

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

  3. Chen, Kexin

    1. Living biobank-based cancer organoids: prospects and challenges in cancer research
      Haixin Li, Hongkun Liu and Kexin Chen
      Cancer Biology & Medicine July 2022, 19 (7) 965-982; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0621

  4. Chen, Sheng

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

  5. Chen, Xin

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

  6. Chen, Yongzi

    1. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

  7. Cheng, Jingyi

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

  8. Cheng, Kai

    1. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

  9. Cheng, Runfen

    1. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

  10. Cheng, Zhigang

    1. Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625

  11. Cui, Daxiang

    1. Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416

D

  1. de la Fuente, Jesús M.

    1. Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416

  2. Di, Genghong

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

  3. Ding, Mengjie

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  4. Dong, Meng

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  5. Dou, Jianping

    1. Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625

  6. Dou, Q. Ping

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

  7. Du, Liqing

    1. ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569

F

  1. Feng, Tingting

    1. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

  2. Fu, Xiaorui

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

G

  1. Gao, Fenghua

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  2. Ge, Luna

    1. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

H

  1. Han, Yu

    1. Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416

  2. Han, Zhiyu

    1. Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625

  3. Hao, Yali

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

  4. Hou, Yifeng

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

  5. Huang, Liang

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

  6. Huang, Qingtian

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

J

  1. Jiang, Wenna

    1. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

  2. Jiang, Yizhou

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

K

  1. Katsube, Takanori

    1. ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569

L

  1. Lei, Ziying

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

  2. Li, Bin

    1. Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416

  3. Li, Binghui

    1. SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291

  4. Li, Haixin

    1. Living biobank-based cancer organoids: prospects and challenges in cancer research
      Haixin Li, Hongkun Liu and Kexin Chen
      Cancer Biology & Medicine July 2022, 19 (7) 965-982; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0621

  5. Li, Hongjuan

    1. SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291

  6. Li, Junjie

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

  7. Li, Ling

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  8. Li, Xiaofen

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

  9. Li, Xin

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  10. Li, Yangling

    1. Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172

  11. Li, Zhaoming

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  12. Liang, Ping

    1. Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625

  13. Lin, Nengming

    1. Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172

  14. Liu, Fangyi

    1. Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625

  15. Liu, Guangyu

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

  16. Liu, Hongkun

    1. Living biobank-based cancer organoids: prospects and challenges in cancer research
      Haixin Li, Hongkun Liu and Kexin Chen
      Cancer Biology & Medicine July 2022, 19 (7) 965-982; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0621

  17. Liu, Jinbao

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

  18. Liu, Qiang

    1. ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569

  19. Liu, Rui

    1. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

  20. Liu, Xijie

    1. SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291

  21. Liu, Yanlei

    1. Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416

  22. Lu, Chang

    1. SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291

  23. Lu, Qiqi

    1. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

N

  1. Nan, Feifei

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  2. Niu, Songtao

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

P

  1. Pan, Jihong

    1. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

Q

  1. Qu, Feilin

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

R

  1. Rao, Mingjun

    1. Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172

  2. Ren, Li

    1. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

S

  1. Shao, Zhimin

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

  2. Song, Guanhua

    1. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

  3. Sun, Lu

    1. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

  4. Sun, Qiuyang

    1. Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416

  5. Sun, Yi

    1. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

  6. Sun, Yinghui

    1. SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291

  7. Sun, Zhenchang

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  8. Sun, Zhijun

    1. Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies
      Wuyin Wang, Lu Zhang and Zhijun Sun
      Cancer Biology & Medicine July 2022, 19 (7) 948-964; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0049

T

  1. Tang, Bo

    1. Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
      Hongquan Wang, Shuang Wu, Yan Wang and Bo Tang
      Cancer Biology & Medicine July 2022, 19 (7) 945-947; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0299

  2. Tang, Daolin

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

  3. Tang, Fan

    1. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

W

  1. Wang, Bing

    1. ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569

  2. Wang, Hongquan

    1. Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
      Hongquan Wang, Shuang Wu, Yan Wang and Bo Tang
      Cancer Biology & Medicine July 2022, 19 (7) 945-947; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0299

  3. Wang, Jing

    1. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

  4. Wang, Liao

    1. SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291

  5. Wang, Lin

    1. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

  6. Wang, Shiguan

    1. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

  7. Wang, Wenhua

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  8. Wang, Wuyin

    1. Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies
      Wuyin Wang, Lu Zhang and Zhijun Sun
      Cancer Biology & Medicine July 2022, 19 (7) 948-964; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0049

  9. Wang, Xinhua

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  10. Wang, Yan

    1. Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
      Hongquan Wang, Shuang Wu, Yan Wang and Bo Tang
      Cancer Biology & Medicine July 2022, 19 (7) 945-947; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0299
    2. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
    3. ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569

  11. Wang, Zhen

    1. Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625

  12. Wang, Zhuozhi

    1. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

  13. Wen, Kaixue

    1. ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569

  14. Wu, Jingjing

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  15. Wu, Linwen

    1. Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172

  16. Wu, Shuang

    1. Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
      Hongquan Wang, Shuang Wu, Yan Wang and Bo Tang
      Cancer Biology & Medicine July 2022, 19 (7) 945-947; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0299

  17. Wu, Xiaolong

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

X

  1. Xie, Yi

    1. ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569

  2. Xu, Chang

    1. ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569

  3. Xu, Shuang

    1. Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172

  4. Xue, Qian

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

Y

  1. Yan, Ding

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

  2. Yan, Jiaqian

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  3. Yang, Benglong

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

  4. Yang, Chuanzhen

    1. SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291

  5. Yang, Ronghui

    1. SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291

  6. Yang, Yuming

    1. Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416

  7. Yao, Leyi

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

  8. Yu, Hui

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  9. Yu, Jie

    1. Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625

  10. Yu, Keda

    1. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

  11. Yu, Xiaoling

    1. Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625

  12. Yue, Caixia

    1. Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416

Z

  1. Zhang, Chong

    1. Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172

  2. Zhang, Hong

    1. ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569

  3. Zhang, Jieming

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  4. Zhang, Lei

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  5. Zhang, Lu

    1. Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies
      Wuyin Wang, Lu Zhang and Zhijun Sun
      Cancer Biology & Medicine July 2022, 19 (7) 948-964; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0049

  6. Zhang, Mingzhi

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  7. Zhang, Qingyun

    1. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

  8. Zhang, Xinwei

    1. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

  9. Zhang, Xudong

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  10. Zhang, Zuoyan

    1. Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172

  11. Zhao, Qian

    1. Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

  12. Zhao, Ru

    1. IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

  13. Zhou, Dongmei

    1. Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172

  14. Zhou, Zhiyuan

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  15. Zhu, Linan

    1. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

  16. Zuo, Duo

    1. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516
Back to top

In this issue

Cancer Biology & Medicine: 19 (7)
Cancer Biology & Medicine
Vol. 19, Issue 7
15 Jul 2022

Submit

Sign up for alerts